Western Hemisphere

Eli Lilly Backs Boston Biotech's Bid to Make Gene Therapy Reversible

Remedium Bio, a preclinical-stage biotechnology company based in Boston, Massachusetts, announced the initial close of a $10M Series A financing round. The round is led by Lifespan Vision Ventures, with participation from pharmaceutical giant Eli Lilly and Company and HKX Capital. As part of the deal, Harry Robb of Lifespan Vision Ventures has joined Remedium's board of directors. The company, led by CEO and co-founder Frank Luppino, says it expects to bring in additional investors before the round's final close.

The financing will fund Remedium's Prometheus platform, which is designed to turn adipocytes — fat cells — at the site of a minimally invasive subcutaneous injection into long-term, adjustable producers of therapeutic proteins. Rather than repeatedly dosing patients with a protein drug, the approach delivers genetic instructions that let a patient's own cells manufacture the protein, potentially for years, while allowing physicians to later adjust expression levels. Proceeds will support Remedium's lead programs and preparations for its first human clinical trials.

Market Context

Remedium's raise arrives as gene therapy increasingly pushes beyond its traditional home in rare disease toward chronic, high-prevalence conditions like obesity and type 2 diabetes — markets currently dominated by GLP-1 drugs that require ongoing injections. The company's pitch is that a single adjustable treatment could reduce the cost and logistical burden associated with lifelong biologic therapy, while sidestepping the redosing and immune-response problems that have limited systemic gene therapy in the past.

The deal also reflects a broader pattern in 2026 biotech financing: corporate venture arms of large pharmaceutical companies are increasingly co-investing alongside specialist VCs in early-stage platforms rather than waiting for later-stage validation. Lilly's participation follows a research collaboration it struck with Remedium in September 2025 focused on gene therapies for type 2 diabetes and obesity, making this financing round something of a deepening of an existing relationship rather than a first bet.

**Frank Luppino, CEO and Co-Founder, Remedium Bio**

"Today, even highly effective preventive medicines depend on patients taking them week after week, often for decades. The shift would be fundamental."
— Frank Luppino, CEO and Co-Founder, Remedium Bio

Regional Relevance

For the United States: The round underscores how large U.S. pharmaceutical companies are moving earlier into platform bets rather than waiting to license approved assets — a shift with implications for how biotech capital gets deployed nationally. Lilly's continued involvement, following its 2025 collaboration with Remedium, signals confidence that adjustable gene delivery could eventually compete with its own blockbuster GLP-1 franchise in obesity and diabetes, a multi-billion-dollar category currently reshaping U.S. healthcare spending.

For Massachusetts: Remedium's Boston headquarters places it squarely within one of the world's densest biotech clusters, where proximity to research institutions, specialized talent, and venture capital continues to draw early-stage life sciences companies. A preclinical company attracting a strategic pharma investor at the Series A stage reinforces Boston's position as a hub where big pharma increasingly sources — and co-develops — next-generation platform technology rather than acquiring it later.